Nanosphere Blood Infection Test Gets Moderate-Complexity Designation | GenomeWeb

NEW YORK (GenomeWeb News) – Nanosphere said after the close of the market Thursday that the US Food and Drug Administration has designated its Gram-Positive Blood Culture nucleic acid test as a moderate-complexity test under CLIA.

The test runs on the firm's Verigene System and provides genes- and species-level detection for a broad panel of clinically significant Gram-positive bacteria. It also detects the mecA, vanA, and vanB genes that identify resistance to the antibiotics methicillin/oxacillin and vancomycin.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.